Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alfacell (ACEL) -- Ignore unavailable to you. Want to Upgrade?

To: leighton stallones who wrote (1405)	6/23/1998 9:15:00 AM
From: Tom DuBois	Read Replies (2) \| Respond to of 1533

Leighton You are a broker, clearly more experienced than I in market dynamics. I have asked this question at least twice before and have never generated a response. Let me try again. Based on your experience as a broker, does it concern you at all that we have a company with a drug well into Phase III trials with allegedly promising efficacy against a terminal disease with no known cure or effective treatment that is selling for less than $3 on anemic daily volume? We can all cite numerous examples of biotechs selling at reasonable valuations (not hype-driven ala Entremed) with much less apparent promise and broad applicability than Onconase at much earlier stages of FDA trials. IF, the Onconase trials are on track, don't you agree ACEL should be commanding a much higher multiple? Leighton, you and rpg regularly accuse those of us who have grown impatient as being "naive, amateurish, greedy, uninformed" etc. I believe you do a disservice to some of my fellow "complainers", and even if I plead guilty to all the above (except greedy, I've only been in for 8+ years now)), I would ask you again for a factual response. Help me end my naivete'...as an "amateur" investor, should I be concerned that this company can still be bought for $2+ at this late date? Are you concerned?? Tom

To: leighton stallones who wrote (1405)	7/15/1998 11:19:00 AM
From: Fish	Read Replies (1) \| Respond to of 1533

Leighton - I resented your personal attack in post # 1405 in which you stated how naive and amateurish I was in regard to being negative on Alfacell. I think the results issued today demonstrate your incompetence. As I had pointed out, the handwriting has been on the wall for the past year - when Mike Lowe resigned and he was not replaced. I fail to see any criminal intent on the part of Alfacell. The study was probably well conducted and the results speak for themselves. Leaking results prior to study completion would have been unethical. As for the Aries Fund, they saw an opportunity and took advantage of it. They did not need any information on study results from Alfacell to act as they did.